PARP1 hyper-activation is associated with many various characteristics of early nephropathy related to type 1 diabetes, which provides a theoretical basis for developing and studying PARP1 inhibitors and PARP1 inhibitor-containing combination therapies [102]. The gene discussed is PARP1; the disease is type 1 diabetes mellitus.